Asahi Kasei offers to buy Calliditas Therapeutics for $1.1B
60% off Profit Pro - Limited Time Offer!
10.53BUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
-
CUSIP
043400100
Sector
Basic Materials
Industry
Chemicals
Fiscal Year End
March
IPO date
-
Updated At
-
PE Ratio
22.35
PEG Ratio
-
Book Value
1,377.42
Dividend Share
36
Dividend Yield
3.06%
Earnings Share
0.34
Wall Street Target Price
-
EPS Estimate Current Year
0
EPS Estimate Next Year
0
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
2,870,073,098,240
Gross Profit TTM
769,768,000,000
EBITDA
351,635,013,632
Profit Margin
2.38%
Return On Assets TTM
2.85%
Return On Equity TTM
3.81%
Revenue Per Share TTM
2070.508
Qtly Revenue Growth YOY
13.10%
Diluted Eps TTM
0.34
Qtly Earnings Growth YOY
255.40%
Trailing PE
22.35
Forward PE
0
Price Sales TTM
0.0037
Price Book MRQ
0.8308
Enterprise Value Revenue
0
Enterprise Value EBITDA
8
69.08
0.99%16.48
0.98%32.70
0.62%11.05
0.55%40.23
0.35%13.57
0.22%43.50
0.00%2.58
0.00%900.00
0.00%26.64
-5.27%Asahi Kasei offers to buy Calliditas Therapeutics for $1.1B
Asahi Kasei Medical to acquire US-based biopharmaceutical CDMO Bionova Scientific